Orforglipron Pill: What We Know So Far
Orforglipron is a new pill being developed by the pharmaceutical company Eli Lilly to treat obesity and type 2 diabetes. It’s currently in the final stages of development.
The pill works by mimicking the effects of injectable GLP-1 drugs, which help with weight loss and blood sugar management.
While it has not received FDA approval yet, Orforglipron is being studied as a potential oral alternative to injectable GLP-1s such as Ozempic and Mounjaro.
Orforglipron is still in the final stages of clinical research and has not been FDA-approved at the time of publication. It isn’t legally available for purchase, and any site claiming to sell it is not legitimate.
Orforglipron works by mimicking a natural hormone called GLP-1 in the body that controls appetite and digestion.
Eli Lilly’s Phase 3 Ofroglipron trial suggests it may help a person feel full faster, eat less, and slowly digest food, potentially supporting weight loss. It may also improve cholesterol, blood pressure, and inflammation, supporting overall heart and metabolic health.
The pill is designed to be taken once daily, with no restrictions on food or drinks.
In August 2025, Eli Lilly announced the results of a late-stage Phase 3 trial. This trial was designed to evaluate the drug’s effectiveness and safety in a large group of people. Phase 3 is usually the final step before a company can apply for regulatory approval to sell a medication.
This trial specifically studied adults with obesity, or those who were overweight with at least one weight-related health condition, and followed participants for 72 weeks.
By the end of the trial, participants taking the highest dose (36 mg) experienced significant weight loss compared with the placebo group:
The trial also showed improvements in cardiovascular risk factors, including cholesterol, triglycerides, and blood pressure.
Most GLP-1 treatments are peptides, which means they consist of chains of amino acids that break down in the digestive system. As a result, they usually need to be injected, sometimes daily or weekly.
Some oral options exist, like Rybelsus, but they come with strict dosing requirements. To ensure proper absorption, a person needs to take this medication on an empty stomach and wait a set time before eating.
Orforglipron, by contrast, is a small-molecule drug. Unlike peptides, small molecules are simple chemical compounds that are stable in the digestive system, which means the drug can be taken as a pill without strict timing restrictions.
This also makes Orforglipron potentially cheaper and easier to manufacture and distribute than injectable drugs. It may also offer a convenient alternative to people who prefer a pill over an injection.
Orforglipron was generally well tolerated in the trial. The most common mild to moderate digestive side effects included:
No liver-related safety concerns were observed. As with all medications, these results reflect trial conditions, and the full safety profile will become clearer once the drug is used in larger, more diverse populations.
Eli Lilly has announced that it plans to submit Orforglipron to the FDA for regulatory review this year (2025) for weight loss, and in 2026 for type 2 diabetes. If approved, Eli Lilly expects to launch Orforglipron globally.
As Orforglipron is still in development, pricing has not been announced. Orforglipron’s developers say the cost “will reflect the medicine’s value and aims to ensure it is accessible to those who need it.”
While Orforglipron has not yet been approved for use, Rybelsus is an alternative oral GLP-1 that is currently approved for type 2 diabetes management.
Some healthcare professionals may prescribe it off-label for weight loss, but it is not FDA-approved for this purpose.
Unlike Orforglipron, however, a person needs to take this medication on an empty stomach and wait a set time before eating.
Alternatively, Contrave is a prescription-only, FDA-approved weight loss pill that is typically taken 1 to 2 times daily.
Contrave is not a GLP-1 medication. Rather, it combines two medications, naltrexone and bupropion, which act on areas of the brain that control hunger and cravings.
A person should talk with a healthcare professional if they are considering starting a weight loss medication.
If a person wants to learn more about weight management and GLP-1s, they might consider talking with a doctor or pharmacist. They can also read the articles below to learn more.
Tirzepatide is an an injectable medication that helps control blood sugar and appetite. It’s sold as Mounjaro for type 2 diabetes and as Zepbound for weight management.
Orforglipron, by contrast, is a pill currently in development for the treatment of type 2 diabetes and obesity, with an FDA decision expected in 2025.
Both drugs mimic the hormone GLP-1, which helps regulate blood sugar and appetite, but tirzepatide also targets another pathway called glucose-dependent insulinotropic polypeptide (GIP).
Tirzepatide is an an injectable medication that helps control blood sugar and appetite. It’s sold as Mounjaro for type 2 diabetes and as Zepbound for weight management.
Orforglipron, by contrast, is a pill currently in development for the treatment of type 2 diabetes and obesity, with an FDA decision expected in 2025.
Both drugs mimic the hormone GLP-1, which helps regulate blood sugar and appetite, but tirzepatide also targets another pathway called glucose-dependent insulinotropic polypeptide (GIP).
No, Orforglipron is not FDA approved. Eli Lilly, the company developing the weight loss pill, plans to submit it for regulatory review in 2025 for the treatment of overweight or obesity, and in 2026 for type 2 diabetes.
No, Orforglipron is not FDA approved. Eli Lilly, the company developing the weight loss pill, plans to submit it for regulatory review in 2025 for the treatment of overweight or obesity, and in 2026 for type 2 diabetes.
Yes, Rybelsus is the first and only oral GLP-1 drug currently approved by the FDA for the treatment of type 2 diabetes. While it can lead to weight loss, and is sometimes prescribed off-label for this purpose, it is not officially approved for obesity.
However, Orforglipron is an oral GLP-1 currently in development for the treatment of type 2 diabetes and obesity. An FDA decision is expected in 2025.
Yes, Rybelsus is the first and only oral GLP-1 drug currently approved by the FDA for the treatment of type 2 diabetes. While it can lead to weight loss, and is sometimes prescribed off-label for this purpose, it is not officially approved for obesity.
However, Orforglipron is an oral GLP-1 currently in development for the treatment of type 2 diabetes and obesity. An FDA decision is expected in 2025.
It’s too early to know whether Orforglipron will be covered by insurance, as the drug has not yet been approved and its cost is not yet known. Coverage may also vary depending on individual insurance plans.
It’s too early to know whether Orforglipron will be covered by insurance, as the drug has not yet been approved and its cost is not yet known. Coverage may also vary depending on individual insurance plans.
Orforglipron is a promising oral GLP-1 medication under development by Eli Lilly for weight management and type 2 diabetes.
While early trial results are encouraging, it is not yet FDA-approved and is not available to buy online.
Its developers plan to submit the weight loss pill for regulatory review in 2025 and 2026 for type 2 diabetes.